Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 26, 2025
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial
John M Kirkwood, Peter Mohr, Christoph Hoeller, et al.
Frontiers in Oncology
|
February 24, 2025
Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms
Esther Natalie Oliva, Shien Guo, Jennifer Lord-Bessen, et al.
BMJ Open
|
March 22, 2023
Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia
Ali T Taher, Khaled M Musallam, Vip Viprakasit, et al.
BMJ Open
|
November 14, 2024
Identifying thresholds for meaningful improvements in NTDT-PRO scores to support conclusions about treatment benefit in clinical studies of patients with non-transfusion-dependent beta-thalassaemia: analysis of pooled data from a phase 2, double-blind, placebo-controlled, randomised trial
Ali T Taher, Khaled M Musallam, Vip Viprakasit, et al.
Hemasphere
|
May 10, 2021
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial
Ruben A Mesa, Nicolaas Schaap, Alessandro M Vannucchi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial
Dirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.
Hemasphere
|
May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
BMC Cancer
|
May 30, 2021
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Stéphane Dalle, Laurent Mortier, Pippa Corrie, et al.
Journal of Clinical Medicine
|
January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
Esther Natalie Oliva, Uwe Platzbecker, Guillermo Garcia-Manero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 28, 2019
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
Celeste Lebbé, Nicolas Meyer, Laurent Mortier, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
European Journal of Cancer (Oxford, England : 1990)
|
March 26, 2025
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial
John M Kirkwood, Peter Mohr, Christoph Hoeller, et al.
Frontiers in Oncology
|
February 24, 2025
Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms
Esther Natalie Oliva, Shien Guo, Jennifer Lord-Bessen, et al.
BMJ Open
|
March 22, 2023
Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia
Ali T Taher, Khaled M Musallam, Vip Viprakasit, et al.
BMJ Open
|
November 14, 2024
Identifying thresholds for meaningful improvements in NTDT-PRO scores to support conclusions about treatment benefit in clinical studies of patients with non-transfusion-dependent beta-thalassaemia: analysis of pooled data from a phase 2, double-blind, placebo-controlled, randomised trial
Ali T Taher, Khaled M Musallam, Vip Viprakasit, et al.
Hemasphere
|
May 10, 2021
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial
Ruben A Mesa, Nicolaas Schaap, Alessandro M Vannucchi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial
Dirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.
Hemasphere
|
May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
BMC Cancer
|
May 30, 2021
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Stéphane Dalle, Laurent Mortier, Pippa Corrie, et al.
Journal of Clinical Medicine
|
January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
Esther Natalie Oliva, Uwe Platzbecker, Guillermo Garcia-Manero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 28, 2019
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
Celeste Lebbé, Nicolas Meyer, Laurent Mortier, et al.
Page
of 3